Elicio Therapeutics, Inc. (ELTX)
2.74
-0.10
(-3.52%)
USD |
NASDAQ |
Aug 31, 13:05
Elicio Therapeutics Free Cash Flow : -37.71M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -37.71M |
| March 31, 2026 | -38.49M |
| December 31, 2025 | -36.97M |
| September 30, 2025 | -38.94M |
| June 30, 2025 | -35.13M |
| March 31, 2025 | -35.15M |
| December 31, 2024 | -37.16M |
| September 30, 2024 | -38.26M |
| June 30, 2024 | -36.22M |
| March 31, 2024 | -36.73M |
| December 31, 2023 | -32.76M |
| September 30, 2023 | -30.24M |
| Date | Value |
|---|---|
| June 30, 2023 | -30.39M |
| March 31, 2023 | -15.34M |
| December 31, 2022 | -22.83M |
| September 30, 2022 | -29.86M |
| June 30, 2022 | -39.73M |
| March 31, 2022 | -56.09M |
| December 31, 2021 | -53.02M |
| September 30, 2021 | -18.05M |
| June 30, 2021 | -24.73M |
| March 31, 2021 | -26.77M |
| December 31, 2020 | -22.93M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Precigen, Inc. | -115.22M |
| Agenus, Inc. | -98.50M |
| Amgen, Inc. | 10.18B |
| Anika Therapeutics, Inc. | 0.562M |
| BioCryst Pharmaceuticals, Inc. | 356.23M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -8.165M |
| Cash from Financing (Quarterly) | 16.51M |
| Free Cash Flow Per Share (Quarterly) | -0.4243 |
| Free Cash Flow to Equity (Quarterly) | -7.973M |
| Free Cash Flow to Firm (Quarterly) | -7.755M |
| Free Cash Flow Yield | -76.51% |